Procurement Summary
Country: Japan
Summary: A Durvalumab (Genetical Recombination) (500mg 10ml/vial) 97vials
Deadline: 13 May 2026
Posting Date: 23 Mar 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 138281483
Document Ref. No.:
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_detailsLogin to see details
Tender Details
A Durvalumab (Genetical Recombination) (500mg 10ml/vial) 97vials
Classification :
0004 Medical & Pharmaceutical Products
Summay of Notice :
⑴ Official in charge of disbursement of the procuring entity : HOUKIN Kiyohiro, President, The National University Corporation Hokkaido University
⑵ Classification of the products to be procured : 4
⑶ Nature and quantity of the products to be purchased :
A Durvalumab (Genetical Recombination) (500mg 10ml/vial) 97vials
B Atezolizumab (Genetical Recombination) (1200mg 20.0ml/vial) 39vials
C Pembrolizumab (Genetical Recombination) (100mg 4ml/vial) 296vials
D Vutrisiran Sodium (25mg 0.5ml/syringe) 4syringes
E Tisagenlecleucel 1set
F Axicabtagene Ciloleucel 2sets
G Lisocabtagene Maraleucel 2sets
H Idecabtagene Vicleucel 1set
Ⅰ Onasemnogene Abeparvovec 1set
J Delandistrogene Moxeparvovec 1set
⑷ Delivery period : From 1 June, 2026 through 31 May, 2027
⑸ Delivery place : Hokkaido University Hospital
⑹ Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A The following shall apply for each of the subjects listed in 5⑶ above.
A
B have the Grade A, Grade B, Grade C or Grade D qualification during fiscal 2026 in the Hokkaido area in Sales of products for participating in tenders by Single qualification for every ministry and agency, or in tenders by Hokkaido University,
C
J have the Grad...
Documents
Tender Notice